Logo

Quidel's Lyra SARS-CoV-2 Assay Receives the US FDA's Expanded Emergency Use Authorization for Molecular Detection of COVID-19

Share this

Quidel's Lyra SARS-CoV-2 Assay Receives the US FDA's Expanded Emergency Use Authorization for Molecular Detection of COVID-19

Shots:

  • Quidel’s Lyra SARS-CoV-2 Assay has received expanded FDA’s EUA to allow testing with three additional thermocyclers: Applied Biosystems 7500 Standard- Roche LightCycler 480- and Qiagen Rotor-Gene Q
  • Under the initial EUA- the Lyra SARS-CoV-2 assay was intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasal/ oropharyngeal swab specimens from suspected COVID-19 patients
  • Additionally- the Lyra SARS-CoV-2 assay has received the CE-Mark and Health Canada’s authorization which allows it to launch in the EU and Canada respectively. The assay is currently available in the US under the EUA

Click here ­to­ read full press release/ article | Ref: Quidel | Image:  Rebrand


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions